Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes.
Mudaliar S, Henry RR, Ciaraldi TP, Armstrong DA, Burke PM, Pettus JH, Garhyan P, Choi SL, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen NK, Sinha VP, Linnebjerg H, Jacober SJ. Mudaliar S, et al. Among authors: sinha vp. Diabetes Obes Metab. 2016 Oct;18 Suppl 2:17-24. doi: 10.1111/dom.12753. Diabetes Obes Metab. 2016. PMID: 27723226 Clinical Trial.
Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects.
Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H. Henry RR, et al. Among authors: sinha vp. Diabetes Care. 2014 Sep;37(9):2609-15. doi: 10.2337/dc14-0210. Epub 2014 Jun 19. Diabetes Care. 2014. PMID: 24947791 Clinical Trial.
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.
Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ. Bergenstal RM, et al. Among authors: sinha vp. Diabetes Care. 2012 Nov;35(11):2140-7. doi: 10.2337/dc12-0060. Epub 2012 Oct 9. Diabetes Care. 2012. PMID: 22787177 Free PMC article. Clinical Trial.
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study.
Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ. Rosenstock J, et al. Among authors: sinha vp. Diabetes Care. 2013 Mar;36(3):522-8. doi: 10.2337/dc12-0067. Epub 2012 Nov 27. Diabetes Care. 2013. PMID: 23193209 Free PMC article. Clinical Trial.
Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147.
Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ. Bergenstal RM, et al. Among authors: sinha vp. Diabetes Care. 2013 Jul;36(7):e107-8. doi: 10.2337/dc13-0295. Diabetes Care. 2013. PMID: 23801809 Free PMC article. No abstract available.
77 results